Full Press Release Details
Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
TRIANGLE PARK, N.C., May 7, 2024 - Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical
company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial
markets on Tuesday, May 14, 2024. Management will host a conference call and webcast that day to discuss the Company's financial
and business results.
Call & Webcast Detail:
the conference call, please register using https://register.vevent.com/register/BI137d97d6710341398d6f17d0433dc5b8. Upon registration,
a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.fennepharma.com and
proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company's
website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen
to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.
Fennec Pharmaceuticals Inc. is a specialty
pharmaceutical company focused on the development and commercialization of PEDMARK and PEDMARQSI to reduce the risk of
platinum-induced ototoxicity in pediatric patients. PEDMARK received FDA approval in September 2022 and European Commission
Marketing Authorization in June 2023 for PEDMARQSI. Further, PEDMARQSI received U.K. approval in October 2023. PEDMARK has
received Orphan Drug Exclusivity in the U.S. for seven years of market protection and PEDMARQSI has received Pediatric
Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information,
please visit www.fennecpharma.com.
information, please contact:
Chief Financial Officer
Fennec Pharmaceuticals Inc.
Elixir Health Public Relations